header logo image


Page 41«..1020..40414243..5060..»

Archive for the ‘Arthritis’ Category

Rheumatoid Arthritis Treatment Market Industry Analysis, Trend and Growth, 2017-2027 – Info Street Wire

Friday, December 27th, 2019

Study on the Rheumatoid Arthritis Treatment Market

The comprehensive report published by Future Market Insights (FMI) offers an in-depth intelligence related to the various factors that are likely to impact the demand, revenue generation, and sales of the Rheumatoid Arthritis Treatment Market. In addition, the report singles out the different parameters that are expected to influence the overall dynamics of the Rheumatoid Arthritis Treatment Market during the forecast period 2017-2027.

As per the findings of the presented study, the Rheumatoid Arthritis Treatment Market is poised to surpass the value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% over the assessment period 2017-2027. The report includes a thorough analysis of the upstream raw materials, supply-demand ratio of the Rheumatoid Arthritis Treatment in different regions, import-export trends and more to provide readers a fair understanding of the global market scenario.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.futuremarketinsights.co/reports/sample/REP-GB-3119

The presented study addresses the following queries related to the Rheumatoid Arthritis Treatment Market:

The presented market report dives deep into understanding the business strategies adopted by leading market players in the global Rheumatoid Arthritis Treatment Market. Further, the SWOT analysis for leading market players is enclosed in the report along with the revenue share, pricing analysis, and product overview of each company.

The extensive study on the Rheumatoid Arthritis Treatment Market pinpoints the different factors that are likely to influence the prospects of the Rheumatoid Arthritis Treatment Market in each region.

Decisive Information Enclosed in the report:

Get Access To TOC Covering 200+ Topics athttps://www.futuremarketinsights.co/toc/REP-GB-3119

key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Customized Report As Per Your Requirements athttps://www.futuremarketinsights.co/customization-available/REP-GB-3119

Why Buy from FMI?

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

T (UK): + 44 (0) 20 7692 8790

This post was originally published on Info Street Wire

Read the rest here:
Rheumatoid Arthritis Treatment Market Industry Analysis, Trend and Growth, 2017-2027 - Info Street Wire

Read More...

Drugs for Rheumatoid Arthritis Market 2019 Global Share, Trend, Segmentation and Forecast to 2025 – Market Research Sheets

Friday, December 27th, 2019

Global Drugs for Rheumatoid Arthritis Market research report gives a comprehensive outlook of the markets 2019-2025 and offers an in-depth summary of the current market status, historic, and expected way forward for the Drugs for Rheumatoid Arthritis Market. Additionally, to this, the report provides data on the restraints negatively impacting the markets growth. The report includes valuable information to assist new entrants, as well as established players, to understand the prevailing trends in the Market.

Download Free Sample Copy of Drugs for Rheumatoid Arthritis Market Report: https://dataintelo.com/request-sample/?reportId=73051

Key Objectives of Drugs for Rheumatoid Arthritis Market Report: Study of the annual revenues and market developments of the major players that supply Drugs for Rheumatoid Arthritis Analysis of the demand for Drugs for Rheumatoid Arthritis by component Assessment of future trends and growth of architecture in the Drugs for Rheumatoid Arthritis Market Assessment of the Drugs for Rheumatoid Arthritis Market with respect to the type of application Study of the market trends in various regions and countries, by component, of the Drugs for Rheumatoid Arthritis Market Study of contracts and developments related to the Drugs for Rheumatoid Arthritis Market by key players across different regions Finalization of overall market sizes by triangulating the supply-side data, which includes product developments, supply chain, and annual revenues of companies supplying Drugs for Rheumatoid Arthritis across the globe

Major Players included in this report are as follows AbbVie IncHoffman-La Roche AGAmgen IncPfizer IncBristol-Myers Squibb CoJohnson & JohnsonUCB Biosciences IncMitsubishi Tanabe Pharma CorpBiogen IncMerck & CoMarket Segment by Product TypePharmaceuticalsBiopharmaceuticals

Drugs for Rheumatoid Arthritis Market can be segmented into Product Types as PrescriptionOTC

Drugs for Rheumatoid Arthritis Market can be segmented into Applications as HospitalClinicsOther

To Buy this report, Visit https://dataintelo.com/checkout/?reportId=73051

Drugs for Rheumatoid Arthritis Market: Regional analysis includes:Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)North America (United States, Mexico, and Canada.)South America (Brazil etc.)The Middle East and Africa (GCC Countries and Egypt.)

Target Audience: Drugs for Rheumatoid Arthritis Equipment Manufacturers Traders, Importers, and Exporters Raw Material Suppliers and Distributors Research and Consulting Firms Government and Research Organizations Associations and Industry Bodies

Stakeholders, marketing executives and business owners planning to refer a market research report can use this study to design their offerings and understand how competitors attract their potential customers and manage their supply and distribution channels. When tracking the trends researchers have made a conscious effort to analyse and interpret the consumer behaviour. Besides, the research helps product owners to understand the changes in culture, target market as well as brands so they can draw the attention of the potential customers more effectively.

Customize Report and Inquiry for The Drugs for Rheumatoid Arthritis Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=73051

Report structure:In the recently published report, DataIntelo.com has provided a unique insight into the Drugs for Rheumatoid Arthritis Industry over the forecasted period. The report has covered the significant aspects which are contributing to the growth of the global Drugs for Rheumatoid Arthritis Market. The primary objective of this report is to highlight the various key market dynamics listed as drivers, trends, and restraints.

These market dynamics have the potential to impact the global Drugs for Rheumatoid Arthritis Market. This report has provided the detailed information to the audience about the way Drugs for Rheumatoid Arthritis industry has been heading since past few months and how it is going to take a shape in the years to come.

DataIntelo has offered a comprehensive analysis of the Drugs for Rheumatoid Arthritis industry. The report has provided crucial information about the elements that are impacting and driving the sales of the Drugs for Rheumatoid Arthritis Market. The section of competitive landscape keeps utmost importance in the reports published by DataIntelo. Competitive landscape section consists of key market players functioning in the worldwide industry of Drugs for Rheumatoid Arthritis.

The report has also analysed the changing trends in the industry. Several macroeconomic factors such as Gross domestic product (GDP) and the increasing inflation rate is expected to affect directly or indirectly in the development of the Drugs for Rheumatoid Arthritis Market.

Table of Contents1 Industry Overview of Drugs for Rheumatoid Arthritis2 Manufacturing Cost Structure Analysis3 Development and Manufacturing Plants Analysis of Drugs for Rheumatoid Arthritis4 Key Figures of Major Manufacturers5 Drugs for Rheumatoid Arthritis Regional Market Analysis6 Drugs for Rheumatoid Arthritis Segment Market Analysis (by Type)7 Drugs for Rheumatoid Arthritis Segment Market Analysis (by Application)8 Drugs for Rheumatoid Arthritis Major Manufacturers Analysis9 Development Trend of Analysis of Drugs for Rheumatoid Arthritis Market10 Marketing Channel11 Market Dynamics12 Conclusion13 Appendix

Ask for Discount on Drugs for Rheumatoid Arthritis Market Report at: https://dataintelo.com/ask-for-discount/?reportId=73051

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info DataInteloName Alex MathewsEmail [emailprotected]Website https://dataintelo.comAddress 500 East E Street, Ontario, CA 91764, United States.

This post was originally published on Market Research Sheets

See original here:
Drugs for Rheumatoid Arthritis Market 2019 Global Share, Trend, Segmentation and Forecast to 2025 - Market Research Sheets

Read More...

Global Septic Arthritis Treatment Market Growth (Status and Outlook) 2019-2024 | Exclusive Report by Magnifier Research – Market Research Sheets

Friday, December 27th, 2019

Global Septic Arthritis Treatment Market 2019 by Company, Regions, Type and Application, Forecast to 2024offers an orderly representation of the market that proposes a positive growth rate in the upcoming years. The report contains the combinations, methods, summarized study, and data gathered from various sources. The research experts have studied the historical data and provided an idea of the direction this market will take in the forthcoming years. The report involves key insights pertaining to industry deliverables, particularly market trends, market share, market competitors and recognized players, market size, current valuation, and revenue estimations for the forecast period from 2019 to 2024. The research study is reliable, wide-ranging, and the result of strong analytical research on theSeptic Arthritis Treatmentmarket.

Get Free Sample Copy of Report/Sample Request @https://www.magnifierresearch.com/report-detail/5571/request-sample

The report investigates evaluates theSeptic Arthritis Treatmentmarket on the basis of market segments and geographical areas and current market trends. Various factors such as development, rapidly increasing demand, economic stability are directly and indirectly fuelling growth in the market are also covered in the report. An assessment of the technical barriers, other issues, as well as market restraints is determined. Key market competitors who majorly hold the market shares in terms of demand, supply, and income through their products, services, and after deal processes are studied and their comprehensive abstract has been provided in the report.

The report encloses a precise evaluation of theSeptic Arthritis Treatmentmarket, including growth rate, current scenario, and volume inflation prospects, on the basis of Porters Five Forces analysis. It provides reliable and authentic projections regarding the market. The report has thoroughly studied the market report on the basis of R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue.

Lupin Pharmaceuticals (US), F. Hoffmann-La Roche Ltd (Swtizerland), AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Pfizer (US),

The global version of this report with a geographical classification such as:

North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Get Full Report With TOC @https://www.magnifierresearch.com/report/global-septic-arthritis-treatment-market-2019-by-company-5571.html

This comprehensive report will

Moreover, manufacturing base distribution, production area, and product type, concentration rate mergers & acquisitions, expansion are provided in the report. The report further has included a new project SWOT analysis, investment feasibility analysis, investment return analysis, and development trend analysis. It also delivers vital information referring to the industrys concentration ratio.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

This post was originally published on Market Research Sheets

Link:
Global Septic Arthritis Treatment Market Growth (Status and Outlook) 2019-2024 | Exclusive Report by Magnifier Research - Market Research Sheets

Read More...

Auranofin Market Status And Forecast 2027, By Players, Types And Applications – Market Research Sheets

Friday, December 27th, 2019

Auranofin is a gold-containing salt with chemical formula and name C20H34AuO9PS and Gold, 2,3,4,6 tetraacetate respectively. It is used for treatingarthritis and is classified as an antirheumatic agent by World Health Organization and is also called disease-modifying antirheumatic drug (DMARD). Antirheumatic drugs are the ones that are used in the treatment of rheumatism. Auranofin is known by different names in different countries. Auranofin improves arthritis symptoms like painful, tender and swollen joints and morning stiffness. Also, it is said to decrease the pain by reducing inflammation and it slows down or stops the immune system from attacking the joints and Auranofin acts by inhibiting DNA synthesis. Auranofin should be considered only when other non-steroidal anti-inflammatory drugs and appropriate steroids are ineffective in controlling the symptoms of rheumatoid arthritis.

The use of Auranofin is increasing as the number of people having arthritis is increasing. This can driveauranofin marketas it is effective and is reported to exhibit less serious side effects as compared to other drugs that are used for treating arthritis.

Planning to lay down future strategy? Perfect your plan with ourreport brochurehere

Increasing Demand for Auranofin Owing to Rising Arthritis Demographics

According to CDC reports, arthritis is still a serious health crisis in the U.S. and it is a global epidemic as well. Recent estimates showed that nearly 91 million Americans might have arthritis (37%), including one- third of those aged bwtween18 to 64 plus 300,000 children approximately. The underlying reasons for the increasing population with arthritis are obesity, lack of physical activity, Vitamin D deficiency and others. Also, Arthritis is rising in Europe, Latin America and in Middle East Africa and reasons being sedentary lifestyle and in some cases, heredity. The growing population with arthritis is anticipated to fuel the Auranofin market as it is less severe than the other drugs that serve the same purpose.

Want to know the obstructions to your companys growth in future?Request a Custom reporthere

The Auranofin market is rising because of the growing arthritis population and it is expected to grow in the coming years. The key players of Auranofin include Ferro Pfanstiehl Laboratories, Inc.,Prometheus laboratories inc, JOHNSON MATTHEY INC, Lek Pharmaceuticals d.d, Medichem SA and Company Overview ofLonza Group Ltd and others. Apart from them, more industrialists and manufacturers are showing a keen interest in the Auranofin as the demand for the auranofin, due to the rising population with arthritis is growing and is expected to escalate until and unless people dont practice healthy lifestyle and engage themselves in physical activities.

This post was originally published on Market Research Sheets

View original post here:
Auranofin Market Status And Forecast 2027, By Players, Types And Applications - Market Research Sheets

Read More...

‘Your Songs Will Live On. You Will Be Missed.’ Rick Charette Leaves The Stage – Maine Public

Friday, December 27th, 2019

Beloved Maine childrens singer Rick Charette and his Bubblegum Band played their 29th annual holiday concert at St. Josephs College earlier this month. It was a sold-out show, standing room only. As always, the price of admission was a new, unwrapped toy for a child in need.

Its likely to be Charettes final public performance ever.

Health challenges are forcing the 72-year-old author of Alligator in the Elevator and I Love Mud off the stage. But he doesnt want to make a big deal of it.

Id like to have people thinking of the music when they think of me, rather than my physical condition, Charette said. Thats why Im downplaying it.

He hinted at his retirement back in 2018, and while Charette is reluctant to talk about specifics, he said a combination of arthritis, a nagging shoulder injury and a touch of Parkinsons disease are making it difficult to perform his energetic shows. Charette would rather stop while hes still at the top of his game, rather than fizzle out and fade away.

I knew I should have said something about it being the last one, but I just couldnt bring myself to do it, Charette said. It would have been just too sad.

For now, hes telling people who want to book him to call back in the spring, when he might feel better. Charettte knows thats not likely, though.

Im ever hopeful but still accepting that, at some point, some things are the way they are, he said.

In the meantime, Charette can look back on an exceptional 35-year career of writing, singing and making children happy.

Charette grew up in Westbrook. When he graduated from Cheverus High School in 1965, music was already a big part of his life.

Pete Seeger was my hero in terms of what he could do to have the whole audience in the palm of his hand, singing along, Charette said over a cup of coffee at his kitchen table in Windham.

He also admired Bob Dylans songwriting.

While earning a degree in English at the University of Southern Maine, Charette found moderate local success as a folksinger, wielding an acoustic guitar, dulcimers and the occasional banjo. He played the bar and coffeehouse circuit and opened for better-known acts such as Tom Rush.

He wasnt always happy, though.

Playing for adults, I was a nervous wreck, Charette said. It was painful. Then, I played a little bit for kids, and it was a whole different vibe. I seemed to relax and be comfortable.

He knew hed found his niche.

Singing with kids meant he did not have to play in smoky bars anymore where the music was secondary to drinking and gabbing. Kids didnt yell requests for Neil Young all night, either.

I liked the hours a lot better, Charette said.

Bubble Gum was the first childrens song he wrote. Kids immediately latched on to its gentle, bouncing cadence and quirky lyrics: I dont like frog legs cause they smell like feet. You can take away the liver. Give me something sweet Bubble gum, bubble gum. Lots of fun with my bubble gum.

By 1983, Charette had recorded an albums worth of original material. He also scored a distribution deal with Activity Records.

When the record came out, it gave me credibility as a performer for kids, he said.

The company passed on his second batch of songs in 1985. They thought Charettes tunes werent educational enough. They wanted more colors and numbers.

At that juncture, Charette and Roy Clark, his piano player and arranger, hatched a plan. They both mortgaged their homes and started their own company, Pine Point Records. Their first release was the album Alligator in the Elevator.

That went on to sell several hundred thousand copies, Clark said.

Charettes best-known song, I Love Mud, appeared on that record.

All I have to do is sing, Mud, mud, I love mud, and everyone finishes the rest of the chorus, Charette said. And its usually the grown-ups singing loudest.

Clark said its Charettes ability to listen to kids, to take their interests seriously, that makes him a good songwriter. Instead of deciding what a child should be singing, he finds out what kids want to sing about.

Thats special. Thats unique, Clark said.

All told, Pine Point Records released 11 albums by Charette. The latest came in 2016.

With a hit childrens record, Charette was soon playing concerts and teaching school songwriting workshops across the country. Many of Charettes his best-loved songs include hand motions or sign language to help keep wee ones engaged. Skunk, bear and alligator puppets also played prominent roles in his performances.

Its beautiful pandemonium, said bassist Mike Burd of Industry. Burds played in the Bubblegum Band for about three years. Rick is a totally humble, gentle, self-effacing, completely transparent, honest guy. The kids fall all over him and follow him all around. The parents do the same thing and, in many cases, the parents parents did the same thing. He has this multigenerational audience. Everybody knows all the words to every song.

Charette has always shied away from politics or broad moralizing in his songs, focusing instead on warmth, fun and singability.

I just want it to be a happy time for them, he said. I think it makes a difference for kids, later in life just knowing someone cares for them giving them that time to play.

Its been a good life for Charette. Hes a happily married father of three and grandfather of two. Hes a longtime resident of Windham, living in an immaculate condo with access to Sebago Lake. Recently, however, hes started to feel his age.

My 60s were good, Charette said. But it seems like when I hit 70, I hit a wall.

Thats when he had a bicycle accident. Charette broke his collarbone and a few ribs, going down hard on a hidden curb.

The bones healed, but his shoulder has never been the same, making it hard to play the guitar. Charette also has arthritis and Parkinsons disease which hes opening up about for the first time.

Ive been reluctant to put that out there in public, he said. Its just the beginning stages and sometimes, when people know something like that about you, they start treating you differently.

He doesnt want that. Charettes early symptoms are manifesting mostly in tight muscles. They make it hard to move around. His feet often feel leaden, immobile.

I wouldnt want to present that onstage. You want kids dancing around, he said. In my mind, in my head, Im still right there. But physically, its just too difficult.

Looking ahead, Charette dreams of hiking when the weather gets nice again. He also imagines days when he might feel well enough to volunteer singing with children, stuck in the hospital. Hes still thinking up songs, too. Charette recently wrote one about Windham and gave it to a local schoolteacher.

Some days are better than others, and when they are, I try to make the most of them, Charette said.

He thinks about his musical legacy, pondering what its meant to himself and the thousands of children hes sung songs with.

Thats something Ive wondered, Charette said. Will this just be time that was taken up? Will they really remember any of it?

As news of his retirement spreads, hes getting his answer.

Cards, letters and Facebook messages are starting to pour in. People tell him about the impact his music had on their lives and now on their childrens lives.

He performed at my school all the time. I had Ricks records on my Christmas list in the 80s when I was a kid, said Heather Hilton, who grew up in Limington. Last year his downloads were on my sons wish list.

Hilton said her 5-year-old son especially likes Charettes epic song Where Do My Sneakers Go at Night? Hiltons mother, an elementary school teacher, still plays Charettes songs in her classroom and said her pre-K students still love them.

One card Charette received this month reads: From my birthday party in kindergarten, to Baxters first concert, youve made us smile throughout the years. Thank you for your wonderful gift of music. Your songs will live on. You will be missed.

It came with a smiling family portrait and was signed, Allyson, Baxter and Tristan.

After his final concert, one little girl waited in line to meet Charette. When it was her turn, she handed him a crinkled drawing of a snowman. It was signed, in pencil, From Athena.

I dont think its sunk in, yet, Charette said, looking at the drawing and the card. Sometimes, I beat myself up. I wish I could do more. Then, I have to remind myself to feel good about the things Ive already done.

Clark thinks Charettes music will be around long after both of them are gone. He points out that I Love Mud and Alligator in the Elevator are so familiar in the kid world, that many people mistake them for traditional folk songs in the public domain.

That seems to suit Charette just fine.

If I had to sum up the whole thing, Im just so gratified that Ive had this run, this experience, Charette said. Its always been the words and the music and the kids.

This story appears through a media sharing agreement with Bangor Daily News.

Go here to see the original:
'Your Songs Will Live On. You Will Be Missed.' Rick Charette Leaves The Stage - Maine Public

Read More...

Insulin Resistance Linked to Rheumatoid Arthritis Flares – Rheumatology Network

Wednesday, December 25th, 2019

Insulin resistance is independently associated with body mass index (BMI) and synovitis in rheumatoid arthritis patients, shows new research published in Arthritis and Rheumatology.

Led by Ronan H. Mullan of the Trinity Centre for Health Science in Dublin, Ireland, researchers wrote that the findings, which were published December 16, suggest a link between glucose levels and rheumatoid arthritis (RA) inflammation.

RA and type 2 diabetes mellitus (T2MD) share many of the same characteristics. Both are powered by abnormal glucose metabolism and both are associated with insulin resistance and adverse cardiovascular disease outcomes.

In this study, researchers recruited 92 rheumatoid arthritis patients (mean age 59, 66% female) who were assessed for insulin resistance, BMI and rheumatoid arthritis disease activity. Researchers found thatglucose transporters GLUT1 and GLUT4 were heightened in the synovial tissues of rheumatoid arthritis patients, but not in those of osteoarthritis patients. And, GLUT1 was present in increased levels within all layers of the RA synovium. This suggests an independent association between insulin resistance (particularly with obesity) and the degree of RA disease activity and synovitis.

RELATED:Diabetes and RA: Explaining the Similarities

This data provides direct evidence that insulin resistant pathways are preferentially expressed within inflamed tissues in RA. And, they suggest a potential mechanism by which the reprogramming of glucose handling through differential GLUT expression favors the perpetuation of inflammation, researchers wrote.

METFORMIN

Taking metformin, a first-line treatment for type 2 diabetes mellitus, was shown to reduce inflammation in synovial tissue of at least five patients by decreasing the spontaneous production of IL-6, IL-8 and MCP-1 in synovial cells and fibroblasts.

We confirmed that metformin treatment increased the phosphorylation of AMPK and reduced the expression of GLUT1 from synovial fibroblasts. Furthermore, we demonstrated that metformin is capable of altering the cellular metabolic activity. This is consistent with recent studies suggesting metformin promotes resolution of inflammation through altered cellular metabolic activity, researchers wrote.

THE FINDINGS

REFERENCE: Lorna Gallagher Sian Cregan Monika Biniecka, et al. "Insulin Resistant Pathways are associated with Disease Activity in Rheumatoid Arthritis and are Subject to Disease Modification through Metabolic Reprogramming; A Potential Novel Therapeutic Approach," Arthritis and Rheumatolology. Dec. 16, 2019. https://doi.org/10.1002/art.41190

See more here:
Insulin Resistance Linked to Rheumatoid Arthritis Flares - Rheumatology Network

Read More...

Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory…

Wednesday, December 25th, 2019

DetailsCategory: More NewsPublished on Tuesday, 24 December 2019 15:04Hits: 334

-- Agreement Extends to Additional Potential Indications for Filgotinib, Including Ulcerative Colitis, Crohns Disease and Psoriatic Arthritis --

FOSTER CITY, CA, USA & TOKYO, Japan I December 24, 2019 I Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) announced today that Gilead Sciences K.K. (Tokyo, Japan) and Eisai have entered into an agreement for the distribution and co-promotion of filgotinib, an investigational, oral, selective JAK1 inhibitor, in Japan, pending regulatory approval for the treatment of rheumatoid arthritis (RA). Through this collaboration, Gilead Japan will retain responsibility for manufacturing and marketing approval of filgotinib, while Eisai will be responsible for product distribution in Japan in RA and other potential future indications. The companies will jointly commercialize the medicine if approved.

Approximately 600,000 to 1 million people are living with RA across Japan, and despite available options, many still do not experience disease remission. In the global Phase 3 FINCH studies, filgotinib demonstrated durable efficacy and safety results across multiple RA patient populations, including in people with prior inadequate response to methotrexate treatment (MTX), those who were intolerant to one or more biologic treatments and those who were MTX treatment-nave.

We are very pleased to announce this important new partnership with Eisai, which brings together our complementary expertise and commitment in inflammation, to deliver this important new option to patients living with inflammatory diseases in Japan, said Luc Hermans, M.D., President and Representative Director, Gilead Japan.

We have extensive clinical development and commercialization experience spanning more than 20 years in RA and have established a solid RA franchise in Japan, said Hidenori Yabune, President of Eisai Japan, Senior Vice President of Eisai. With this agreement, we look forward to contributing more to patients living with RA by adding filgotinib to our product line-up.

Global studies investigating filgotinib in additional diseases are also underway, including the Phase 3 SELECTION trial in ulcerative colitis, the DIVERSITY Phase 3 trial in Crohns disease, the Phase 3 PENGUIN trials in psoriatic arthritis, as well as Phase 2 studies in uveitis and in small bowel and fistulizing Crohns disease.

Gilead and Galapagos NV (Mechelen, Belgium) have entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. Filgotinib is an investigational drug whose efficacy and safety have not been established. Filgotinib is pending regulatory approval in Japan, Europe and the United States, based on global Phase 3 trials evaluating its efficacy and tolerability.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the companys website at http://www.gilead.com.

About Eisai Co., Ltd.

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit http://www.eisai.com/.

SOURCE: Eisai

See the original post:
Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory...

Read More...

Adults with JIA Satisfied with Biologics But Often Fail to Adhere to Therapy, Study Finds – Juvenile Arthritis News

Wednesday, December 25th, 2019

Adults with juvenile idiopathic arthritis (JIA) treated with disease-modifying antirheumatic drugs (DMARDs) are more satisfied with biological medicines than with synthetic therapies such as methotrexate, a study based on patient questionnaires suggests.

Nonetheless, less than half of these patients took these medications as recommended.

The study, Treatment Satisfaction with and Adherence to DiseaseModifying Antirheumatic Drugs in Adult Patients with Juvenile Idiopathic Arthritis, was published in Arthritis Care & Research.

DMARDs are one class ofmedications currently used to treat JIA, and include both synthetic (chemical compound) medicines, such as methotrexate, and biological therapies.

Following prescribed treatment regimens as recommended (adherence) is a key requirement for clinical benefit. However, studies have found that just over half of rheumatoid arthritis patients comply with treatment regimens.

Such research in JIA has focused on children, but as40-60% of patients continue to experience symptoms into adulthood, a better understanding of the adherence to DMARDs in adults with this disorder is needed.

A team in Norway contacted adults with JIA, who as children had participated in a three-year study. From a total of 196 eligible patients, 96 (mean age of 25.1) agreed to participate.

The researchers collected information about medication use, and patients were given a series of questionnaires, which included a patient reports of active joint swelling.

Satisfaction with treatment was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM), which evaluates effectiveness, side effects, convenience, and overall satisfaction. In turn, medication adherence was assessed using the Morisky Medication Adherence Scale (MMAS-8), where 8 is high adherence and below 6 is low adherence.

Physical and mental health-related quality of life (HRQOL) was determined with the Short-Form Health Survey version 2, physical disability with the Health Assessment Questionnaire Disability Index, pain with the Brief Pain Inventory Short Form, and symptoms of psychological distress with the Hopkins Symptom Checklist.

Nineteen years after their diagnoses, 52 patients (54%) used synthetic DMARDs and/or biological DMARDs. Biological DMARDs were used by 37 patients (39%), either alone or in combination with methotrexate or sulfasalazine. Twenty-eight patients used methotrexate exclusively or in combination with biological DMARDs and sulfasalazine, while two patients used sulfasalazine alone.

Those using biological DMARDs alone reported significantly higher satisfaction with the medication related to effectiveness and overall satisfaction compared to those taking methotrexate. Participants using combination therapy also reported significantly higher satisfaction using biological DMARDs over methotrexate, based on side effects and overall satisfaction.

Lower satisfaction with medications was linked to pain intensity, physical disability, psychological distress, and active joints. Higher satisfaction related to effectiveness was strongly associated with a higher physical HRQOL, while overall satisfaction was linked with better physical and mental HRQOL.

The study also found that 46% of the patients reported low adherence to DMARDs, while 29% reported medium adherence, and 25% had high adherence.

Adherence to treatment was independent of age, gender, disease duration and course, active joints, effectiveness, side effects, and overall satisfaction. Treatment convenience was the only factor significantly linked to medication adherence.

In conclusion, JIA patients medication satisfaction was higher with bDMARDs [biological DMARDs] than MTX [methotrexate] 19 years after disease onset, the researchers wrote.

Knowledge and incorporation of patients experience with medication is important in order to promote patient centered care and achieve the best possible HRQOL, they added.

Total Posts: 11

Jos is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimers disease.

See the original post here:
Adults with JIA Satisfied with Biologics But Often Fail to Adhere to Therapy, Study Finds - Juvenile Arthritis News

Read More...

Think Twice When Choosing Skin Care Products as Gifts for Kids with JA – Juvenile Arthritis News

Wednesday, December 25th, 2019

As I searched online for Christmas presents for my loved ones recently, I browsed selections of pre-made gift kits. Many of them were bath or skin care based. I saw adorable bubble bath sets for children, makeup and nail kits, and baskets of soaps and creams marketed to young men and women.

Skin care products can make lovely gifts. I bought a unicorn tumbler full of bath bombs for my young cousin. But as I shopped, I thought about how I wouldnt buy gifts like these for myself. As someone withjuvenile-onset psoriatic arthritis, I would worry that they might flare my skin. I realized many of these gifts wouldnt be suitable for kids or young adults with juvenile rheumatic conditions.

Additionally, conditions such as systemic arthritis, dermatomyositis, scleroderma, psoriatic arthritis, and lupus can cause rashes, lesions, and other skin issues, which can be further irritated by skin care products.

Those with skin conditions cant usually tolerate the ingredients used in pre-made bath sets and makeup kits. Items such as bath bombs are not recommended for those with particular skin conditions. Other products may be drying and irritating to those with sensitive or inflamed skin.

But that doesnt mean you have to avoid giving pampering gifts altogether. Many kids with juvenile arthritis benefit from the soothing effects of a warm bathand the confidence boost of wearing makeup. Instead, when choosing a gift, consider the products quality.

If youre thinking of giving soaps, makeup, and lotions as gifts dont be afraid to ask the childs parents which products they use. And stick to those brands. Dont be misled by product labels containing words like natural, healing, or even psoriasis-friendly. While the claims might be valid, its best to stick to products that the family already trusts the brands they use are likely either doctor recommended or theyve discovered them after much trial and error.

Quality is essential for those living with chronic skin conditions. Dont be surprised if the products and brands that the person uses are a little expensive. You dont need to break your budget, but remember that its better to choose quality over quantity. A trusted eye shadow palette with one or two colors is worth much more than another with multiple shades that may irritate the skin.

You might also consider gifting skin care accessories such as makeup brushes or sponges, or a cosmetic bag to keep products in.

You could put together a custom-made bath kit. For younger kids, a bath caddy filled with bath toys and crayons, a hooded towel, a brush and comb, and fun, colored puffs. Older kids and teens might prefer bathrobes, slippers, eye pillows, spa socks, and candles or essential oils. I like this idea because you can pick and choose each item and customize it to the recipient.

Ive received lots of bath and beauty products in the past. Many of them came from my parents, who knew how careful I needed to be with skin products. Im always extremely appreciative of the lotions, makeup, and perfumes they gift, particularly as they can be pricey.

Sometimes Ive received products that I didnt feel comfortable using. But I accepted them with a smile and a genuine thank you. Im grateful for the gift of someone thinking of me, taking the time to buy me a gift, and wrap it up.

***

Note: Juvenile Arthritis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Juvenile Arthritis News, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to juvenile arthritis.

Elizabeth Medeiros is a young adult who has dealt with juvenile arthritis since she was a small child. However, her pain hasnt stopped her from working on a product design degree in Boston. Her passion is to create products that make life easier for the chronically ill, such as shoes and walking canes. When shes not in class, Elizabeth enjoys writing about how shes coped with arthritis at such a young age. You can find more of her writings at ArthritisGirl.Blogspot.com and on Instagram @GirlWithArthritis.

See the original post:
Think Twice When Choosing Skin Care Products as Gifts for Kids with JA - Juvenile Arthritis News

Read More...

Global Glucosamine Market 2020-2024 | Evolving Opportunities with Blackmores Ltd. and Cargill Inc. | Technavio – Business Wire

Wednesday, December 25th, 2019

LONDON--(BUSINESS WIRE)--The global glucosamine market is expected to grow by USD 229.19 million during 2020-2024, according to the latest market research report by Technavio, progressing at a CAGR of more than 6% during the forecast period. The market is driven by factors such as increasing use of combination therapy, popularity of e-commerce in the healthcare industry, and rising geriatric population. Request a free sample report

The market research report segments the glucosamine market by application (arthritis and other applications) and geography (Asia, Europe, North America, and ROW).

https://www.technavio.com/report/glucosamine-market-industry-analysis

Glucosamine Application Outlook (Revenue, USD Million, 2020-2024)

Glucosamine finds a large number of applications in the arthritis segment. The market is witnessing a shift toward the use of nutrachemicals and dietary supplements such as glucosamine to treat arthritis without side effects. Globally, the geriatric population is increasing significantly, leading to a prevalence of arthritis as the cartilage is more susceptible to wear with age. These factors are boosting the growth opportunities for market participants in the arthritis segment.

Glucosamine Regional Outlook (Revenue, USD Million, 2020-2024)

North American region led the market in 2019, followed by Europe, Asia, and ROW, respectively. During the forecast period, the North American region will continue to dominate as the largest market for glucosamine. This is due to the increasing sales of OTC glucosamine products and the rising prevalence of joint-related indications such as osteoarthritis. The expansion of the geriatric population in the region is also contributing to the growth of the glucosamine market.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Major Five Genetic Testing Companies:

Blackmores Ltd., Cargill Inc., Ethical Naturals Inc., GNC Holdings Inc., and Herbs Nutriproducts Pvt. Ltd. are among the vendors who have a strong position in the global market.

Blackmores Ltd.

Blackmores Ltd. operates the business across segments such as Australia and New Zealand, China, Other Asia, and BioCeuticals Group. Glucosamine + Fish Oil, Glucosamine Sulfate 1500 One-A-Day, Glucosamine Sulfate Complex 1000, Joint Formula Advanced, Joint Formula with Glucosamine & Chondroitin, and Vegetarian Glucosamine Sulfate Complete 1000 are some of the key offerings of the company.

Cargill Inc.

Cargill Inc. operates the business across segments such as Animal nutrition and protein, Animal nutrition and protein, Food ingredients and applications, Origination and processing, and Industrial and financial services. Regenasure is one of the key offerings of the company. It is glucosamine hydrochloride synthesized from corn. It is available in the form of a granular powder and is certified for Kosher Pareve, Kosher for Passover, and Halal use.

Ethical Naturals Inc.

Ethical Naturals Inc. operates the business through its Unified business segment. GreenGrown, which is glucosamine hydrochloride synthesized from vegetarian sources, is one of the key offerings of the company. It is available in the form of granular powder and can be used for improving joint health.

GNC Holdings Inc.

GNC Holdings Inc. operates the business across segments such as the US and Canada, International, and Manufacturing / Wholesale. GNC GLUCOSAMINE 1000 MG, GNC MSM-GLUCOSAMINE, GNC GLUCOSAMINE SULFATE 500 MG, DOCTOR'S BEST, and GNC TRIPLE STRENGTH GLUCOSAMINE CHONDROITIN are some of the key offerings of the company.

Herbs Nutriproducts Pvt. Ltd.

Herbs Nutriproducts Pvt. Ltd. operates the business across segments such as Natural infusion tea, Cold pressed oils, Functional foods, Vitamins and supplements, and Beauty. Glucosamine Chondroitin Complex with Herbal Extracts is one of the key offerings of the company. It is a combination of glucosamine sulfate and chondroitin available in the form of tablets.

Technavio provides a free sample report which contains multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

See more here:
Global Glucosamine Market 2020-2024 | Evolving Opportunities with Blackmores Ltd. and Cargill Inc. | Technavio - Business Wire

Read More...

Cultural Adaptation and Validation of the Methotrexate Intolerance Severity Score in Brazilian Portuguese for Adults With Rheumatoid Arthritis -…

Wednesday, December 25th, 2019

INTRODUCTION:

The Methotrexate Intolerance Severity Score (MISS) questionnaire is used to identify intolerance to methotrexate (MTX), but it is not available in the Brazilian Portuguese language.

The aim of this study was to adapt and validate the MISS in Brazilian Portuguese.

The Brazilian Portuguese version of the MISS was developed following the Guidelines for the Process of Cross-cultural Adaptation of Self-report Measures. The new version was tested in 120 patients with rheumatoid arthritis. For the reliability assessment, the Cronbach coefficient was used. The receiver operating characteristic curve was constructed with the objective of finding the best cutoff point for MTX intolerance and weighing the sensitivity and specificity. The concordance among the results was analyzed using the coefficient and factorial analysis with varimax rotation.

This methodological study developed and applied a culturally acceptable Brazilian Portuguese version of the MISS. The MISS questionnaire presented internal consistency classified as very good because Cronbach is equal to 0.83 (95% confidence interval, 0.79-0.87). The suitability of the data for factorial analysis was demonstrated using the Kaiser-Meyer-Olkin sample adequacy test (KMO = 0.723) and Bartlett sphericity test ( = 499.98, p < 0.001). It was observed that a factorial analysis with 3 factors is preferred; the receiver operating characteristic curve of the MISS score was considered the cutoff point at 6 points (sensitivity 100% and specificity 89.4%).

The Brazilian Portuguese version of the MISS is valid and reliable for the detection of MTX intolerance in clinical practice.

Visit link:
Cultural Adaptation and Validation of the Methotrexate Intolerance Severity Score in Brazilian Portuguese for Adults With Rheumatoid Arthritis -...

Read More...

Knee injuries in early adulthood may hasten arthritis – Reuters

Monday, December 23rd, 2019

(Reuters Health) - Young adults who have had knee injuries are much more likely than uninjured peers to develop arthritis in the knee by middle age, especially if they have broken bones or torn connective tissue, a recent study suggests.

Researchers followed almost 150,000 adults ages 25 to 34, including about 5,200 with a history of knee injuries, for almost two decades. Compared to people who never had knee injuries, those who did were nearly six times as likely to develop knee osteoarthritis during the first 11 years of follow-up, with more than triple the risk over the next eight years.

Injuries that occur inside the knee joint, for example in the meniscus or cruciate ligament, may alter the biomechanical loading patterns in the knee, said study leader Barbara Snoeker, of Lund University in Sweden.

Such injuries may lead to an imbalance in force transmissions inside the knee joint, consequently overloading the joint cartilage and leading to increased risk of developing osteoarthritis, compared to injuries that mainly affect the outside of the knee joint, such as contusions, Snoeker said by email.

Osteoarthritis often affects the large weight-bearing joints and can eventually lead to the need for total joint replacement, the researchers note in the British Journal of Sports Medicine.

Known risk factors include being overweight, older, female or having a job that puts a lot of stress on the joints, the study team notes. While a history of knee injuries is also a known risk factor, research to date hasnt offered a clear picture of whether certain types of injuries might be more likely to lead to osteoarthritis.

Two-thirds of the people in the study with knee injuries were male. After 19 years of follow-up, 422 people with knee injuries, or 11.3%, developed knee osteoarthritis. So did 2,854, or 4%, of people without knee injuries.

Most often, injuries involved multiple structures of the knee; this accounted for 21% of participant knee injuries. The second most common type of injury was cuts and contusions, at 18%, followed by cartilage or other tissue tears at 17%.

Cruciate ligament injuries, or damage to the tissue connecting the thighbone to the shinbone, were associated with a 19.6% greater risk of knee osteoarthritis, the study also found. Meniscal tears, or damage to cartilage connecting the same two bones, were associated with a 10.5% greater risk of osteoarthritis. Fractures of the shinbone where it meets the knee, or of the kneecap, were associated with a 6.6% greater risk.

Injuries involving multiple structures in the knee may have been underreported, leading researchers to underestimate the risk associated with these types of injuries, Jonas Bloch Thorlund, a professor of musculoskeletal health at the University of Southern Denmark, in Odense, who wasnt involved in the study, said by email.

Another limitation is that researchers didnt look at patients body mass index (BMI), so they couldnt tell whether differences in weight might explain patients risk of osteoarthritis, said Dr. Kyle Hammond of the Emory Sports Medicine Center in Atlanta.

What happens after knee injuries can also influence the risk of osteoarthritis down the line, Hammond, who wasnt involved in the study, said by email.

Counseling a patient on how to safely and consistently return to a positive fitness program ensures that they will maintain flexibility and strength, as well as keeping their weight at their ideal body weight, Hammond advised.

Rehab matters regardless of what other treatments patients receive, said Adam Culvenor, a sports and exercise medicine researcher at La Trobe University in Bundoora, Australia, who wasnt involved in the study.

Once these injuries occur, optimally managing them with an intense and progressive period of rehabilitation under the guidance of a physical therapist (irrespective of the decision to have surgery or not) to strengthen the muscles around the knee to facilitate a return to function and physical activity is likely to reduce the risk of osteoarthritis and persistent symptoms longer-term, Culvenor said by email.

SOURCE: bit.ly/2MhjRto British Journal of Sports Medicine, online December 11, 2019.

View post:
Knee injuries in early adulthood may hasten arthritis - Reuters

Read More...

Family Health West’s Dr.Rook Discusses Spondyloarthritis and Inflammatory Arthritis – KKCO-TV

Monday, December 23rd, 2019

FRUITA,Co.(KKCO)-- Dr.Rooks rheumatologist from the Arthritis Center of Western Colorado at Family Health West stopped by and discussed the difference between Spondyloarthritis and Inflammatory arthritis.

Doctors see a lot of patients with Spondyloarthritis on the Western slope especially among young adults.

Symptoms of Spondyloarthritis are stiffness when you wake up, and inflammation in the spine, hips, and knees.

Inflammatory arthritis is the most common type of arthritis. Symptoms include new joint or tendon pain, swelling, stiffness that lasts more than an hour in the morning without prior injury.

Inflammatory arthritis is actually a systemic disease of the immune system that, if not treated appropriately, can lead to joint and tendon damage, deformities, and contribute to heart attacks, strokes, and more.

If you have more questions on arthritis visit their website http://www.ac-wc.com.

Go here to read the rest:
Family Health West's Dr.Rook Discusses Spondyloarthritis and Inflammatory Arthritis - KKCO-TV

Read More...

Contraceptive Use in Women of Childbearing Ability With Rheumatoid Arthritis – DocWire News

Monday, December 23rd, 2019

BACKGROUND/OBJECTIVE:

Rheumatoid arthritis (RA) is a complex disease that may require treatment with one or several disease-modifying antirheumatic drugs (DMARDs). Many DMARDs have potential teratogenic effects or are newer agents with limited safety data in pregnancy. This study evaluated 20 common RA medications and the rate of contraceptive prescribing and counseling patterns in women with RA of childbearing ability.

This was an observational study of women with RA and childbearing ability aged 18 to 44 years who were seen at an academic rheumatology clinic from April 1, 2014, to March 31, 2016. Descriptive statistics and univariate logistic regression were used for analysis.

One hundred fifty women were included in the analysis. The majority of patients were taking methotrexate (55.3%), followed by chronic prednisone (31.3%) and hydroxychloroquine (28.7%). A documented method of contraception was noted in 64/150 (42.7%). For women on contraception, most used combined oral contraceptives (31/64, 48.4%) or levonorgestrel intrauterine device (10/64, 15.6%). Of the 86 patients not on contraception, 19 (22.1%) received counseling regarding a pregnancy plan.

Most women with RA of childbearing age and ability were not using contraception. Among these patients, only a minority prescribed DMARD therapy had documented pregnancy or contraceptive counseling. Women with RA who were prescribed with a DMARD should discuss the use of effective contraception with their provider if sexually active and not desiring pregnancy or wanting to avoid potential teratogenic effects. Potential strategies are discussed to improve healthcare delivery to this population in hopes of avoiding unintended pregnancy and potential teratogenic effects of RA medications.

Original post:
Contraceptive Use in Women of Childbearing Ability With Rheumatoid Arthritis - DocWire News

Read More...

BYU student connecting ‘lost generation’ honored by Arthritis Foundation – Daily Herald

Monday, December 23rd, 2019

It took 16 years after Ethan Nelsons arthritis diagnosis until he met someone who shared his condition.

There is definitely this generation where if you get diagnosed, you are alone, Nelson said. You dont have anyone.

Nelson, now 22 years old and a junior at Brigham Young University, was diagnosed with systemic juvenile idiopathic arthritis when he was 4 years old. He spent the last two years volunteering for arthritis-related causes and helping to build a network of young adults who share the same condition.

He was honored Dec. 7 in Salt Lake City at the Jingle Bell Run, a 5K that benefits the Arthritis Foundation.

The run honored six people, which also included Kendall Pogue, who is also a BYU student, and Spencer Hood, who, along with Nelson, had tried to connect young adults with arthritis.

Hood first connected Nelson with the Jingle Bell Run two years ago. This year, Nelson led a team and raised $530 of his groups $810 total.

He is a really great guy, said Debbie Jordan, the executive director of the Arthritis Foundation of Utah. You have to think about what it is like for a college kid to get up at 4 a.m. in the morning and help us out.

Jordan said the honorees are volunteers who have done more than the average for the foundation. She said theres typically about 40 BYU students who come to help out at the run.

The young adult volunteers, she said, show children with arthritis that they can still achieve their goals.

I think it gives them a lot of hope, Jordan said.

Its not the first time Nelson has been involved with raising awareness and funding for arthritis. He was the literal poster boy for the National Arthritis Foundation when he was about 5 years old, showing the effects that his treatment at the time, the steroid prednisone, has on the body.

Since then, hes had two hip replacements one when he was 13, the other at 16 and had surgery on his ankle.

He was on the tail end of a generation that exclusively used prednisone, which has been mostly replaced with biologic treatments and IV infusions for young patients. The last two years have been rough as he tried to find a medicine his body responded well to. After trying five different treatments, hes doing well again.

I feel like 100% normal, Nelson said. I can walk without pain.

Hes volunteered at Camp Kids Out to Defeat Arthritis, also known as Camp KODA. While there, he advocates for campers to become independent in order to prevent flare ups and joint damage.

I know these kids very personally now and I dont want my mistakes to rub off on them in the future, Nelson said. So it is like, dont let your arthritis hold you back, dont take advantage of it and stay on top of things.

The Arthritis Foundation estimates that one in four adults have arthritis, which includes 400,000 adults and 3,000 children in Utah.

Nelson said that while someone in their 20s is just as likely to be diagnosed as someone who is 60, young adults often dont talk about having arthritis.

It is so much easier to conceal, to hide, than cancer, and so I feel like people have the opportunity to hide it and so they do from others because they dont want to feel like the odd one out, he said.

While he feels the Arthritis Foundation does well with reaching young children and older adults, Nelson said young adults can be left out. He and Hood are trying to find more young adults who have arthritis for their group, Utah YA Champions. Nelson is also working to create a student association at BYU for students with arthritis.

More:
BYU student connecting 'lost generation' honored by Arthritis Foundation - Daily Herald

Read More...

Tackling Inflammation to Fight Age-Related Ailments – The New York Times

Monday, December 23rd, 2019

Lets start with what to eat and the foods to avoid eating. What follows will likely sound familiar to aficionados of a Mediterranean-style diet: a plant-based diet focused on fruits and vegetables, whole grains, and cold-water fish and plants like soybeans and flax seeds that contain omega-3 fatty acids.

A Mediterranean-style diet is rich in micronutrients like magnesium, vitamin E and selenium that have anti-inflammatory effects, and its high-fiber content fosters lower levels of two potent inflammatory substances, IL-6 and TNF-alpha.

Dr. Frank Hu, professor of nutrition and epidemiology at the Harvard T.H. Chan School of Public Health, strongly recommends limiting or eliminating consumption of foods known to have a pro-inflammatory effect. These include all refined carbohydrates like white bread, white rice and pastries; sugar-sweetened beverages; deep-fried foods; and red meat and processed meats. They are the very same foods with well-established links to obesity (itself a risk factor for inflammation), heart disease and Type 2 diabetes.

In their stead, Dr. Hu recommends frequent consumption of foods known to have an anti-inflammatory effect. They include green leafy vegetables like spinach, kale and collards; fatty fish like salmon, mackerel, tuna and sardines; fruits like strawberries, blueberries, apples, grapes, oranges and cherries; nuts like almonds and walnuts; and olive oil. The recommended plant foods contain natural antioxidants and polyphenols, and the fish are rich in omega-3 fatty acids, all of which counter inflammation.

Coffee and tea also contain protective polyphenols, among other anti-inflammatory compounds.

The bottom line: the less processed your diet, the better.

At the same time, dont neglect regular exercise, which Dr. James Gray, cardiologist at the Scripps Center for Integrative Medicine, calls an excellent way to prevent inflammation. He recommends 30 to 45 minutes of aerobic exercise and 10 to 25 minutes of weight or resistance training at least four to five times a week.

Although exercise is pro-inflammatory while youre doing it, during the rest of the time it leaves you better off by reducing inflammation, and after all you live most of your life not exercising, Stephen Kritchevsky, professor of gerontology and geriatric medicine at Wake Forest School of Medicine, told me. Independent of any effect on weight, exercise has been shown to lower multiple pro-inflammatory molecules and cytokines.

More here:
Tackling Inflammation to Fight Age-Related Ailments - The New York Times

Read More...

DWP: How thousands with arthritis, MS and psychosis have lost benefits under new system – Mirror Online

Monday, December 23rd, 2019

Tens of thousands of people with conditions including arthritis, MS and psychosis have had their benefits cut or stopped after moving to a new Tory system.

Detailed statistics from the Department for Work and Pensions (DWP) show the reality of the 650,000 former Disability Living Allowance claimants who've lost out since 2013.

This week the Mirror reported how 46% of former DLA claimants lost money after moving to new benefit Personal Independence Payment (PIP).

In total, of the 1.424million DLA claimants reassessed for PIP by October 2019, 306,000 (22%) had their benefit cut, 293,000 (21%) had it stopped after an assessment, 58,000 (4%) had it stopped before assessment and 9,000 (1%) withdrew their claim.

In contrast 556,000 claimants (39%) saw their award rise and 200,000 (14%) had it unchanged.

But the DWP's detailed figures give a fascinating insight that show the real people behind the numbers.

The worst-hit were people with psychosis, 87,824 of whom either failed a PIP assessment entirely or had their money cut since 2013. By comparison, 63,395 saw their payment rise.

Some 86,042 arthritis sufferers had their PIP cut or stopped when they moved from DLA - while 68,256 saw it go up.

Scroll down for the full list of disabilities and how they are hit.

Epilepsy sufferers were also badly hit, with 23,640 losing some or all of their benefits compared to 12,344 who received more.

And 10,247 people with MS, 2,188 with AIDS and 960 with cystic fibrosis saw their money either cut or stopped.

Since 2013, even 69 double amputees have had their money cut when moving from DLA to PIP - while 161 saw their award go up.

Some groups were better off on average. 6,533 blind people saw payments cut or stopped but 23,098 saw them rise.

Likewise 39,020 people with learning difficulties lost out but 86,567 were better off.

These figures only relate to claimants who were already on the old DLA system when they claimed PIP.

And they do not include people who lost their benefits before an assessment, failed to attend an appointment, or withdrew their claim.

MS sufferer Rachel Taylor, from Halifax, West Yorkshire, told the Mirror she lost her adapted Motability car for around a year after her benefits were cut moving from DLA to PIP.

The 50-year-old mother-of-one and librarian uses a zimmer frame, walking stick and mobility scooter to get around.

But despite claiming DLA since 2002 she said she was awarded the lower rates of PIP after a 2016 assessment.

She waited around a year until, weeks before her appeal tribunal, she said she received a phone call saying she'd get the higher rate after all.

She told the Mirror: "I ended up taking several thousand pounds out of my pension pot.

"The stress has been immeasurable.

"I take pride in what Im able still able to do. But I now believe I was penalised for trying to keep my independence.

Ms Taylor still works part-time but said "I couldn't be more disabled."

She added: The local bus goes from a mile away but I cant walk to the end of my driveway.

"Theres no hope for me walking to catch a bus. I have a son that I have to get to school."

The DWP said Ms Taylor received 3,000 in arrears and a 2,000 transition payment for the Motability scheme.

A DWP spokesman added: Ms Taylor was granted enhanced level mobility Personal Independence Payment as soon as further evidence became available and a back payment of almost 3,000 was paid in arrears.

The DWP figures were condemned by charities earlier this week. Geoff Firmister of the Disability Benefits Consortium, which represents more than 100 groups, said: "These figures are very worrying and we suspect many of the decisions are wrong."

James Taylor of disability equality charity Scope said the figures were "extremely worrying". He added: Consistently high levels of PIP decisions are being overturned, which demonstrates the assessment is not fit for purpose."

A DWP spokesman said: The Government now spends more than 55 billion every year to support disabled people, more than at any time under the DLA system; with more people benefitting from support through PIP than did under DLA.

Most people get PIP after being reassessed from DLA.

"More than half have their award maintained or increased, with 29% receiving the highest level of support compared to 16% under DLA.

Here are the figures from the government.NOTE: Conditions are exactly as listed by the DWP. Figures only include reassessments from DLA to PIP.

Psychosis - More money: 63395 Less: 37916 Nothing: 49908

Psychoneurosis - More money: 48376 Less: 15408 Nothing: 35587

Learning Difficulties - More money: 86567 Less: 6697 Nothing: 32323

Arthritis - More money: 68256 Less: 65438 Nothing: 20604

Epilepsy - More money: 12344 Less: 8403 Nothing: 15237

Disease Of The Muscles Bones or Joints - More money: 31677 Less: 18572 Nothing: 12543

Back Pain - Other / Precise Diagnosis not Specified - More money: 31193 Less: 33449 Nothing: 8925

Neurological Diseases - More money: 22151 Less: 11918 Nothing: 7647

Heart Disease - More money: 9907 Less: 8829 Nothing: 4893

Chronic Pain Syndromes - More money: 11483 Less: 11254 Nothing: 4552

Hyperkinetic Syndrome - More money: 3737 Less: 1606 Nothing: 4452

Blindness - More money: 23098 Less: 2234 Nothing: 4299

Trauma to Limbs - More money: 10401 Less: 6658 Nothing: 4288

Personality Disorder - More money: 4755 Less: 3802 Nothing: 4165

Malignant Disease - More money: 5226 Less: 5431 Nothing: 3832

Cerebrovascular Disease - More money: 15472 Less: 7819 Nothing: 3631

Diabetes Mellitus - More money: 4560 Less: 3063 Nothing: 3426

Deafness - More money: 8864 Less: 2553 Nothing: 3396

Spondylosis - More money: 10520 Less: 10339 Nothing: 3087

Behavioral Disorder - More money: 3863 Less: 978 Nothing: 2811

Chest Disease - More money: 11761 Less: 8095 Nothing: 2632

Alcohol and Drug Abuse - More money: 4746 Less: 1900 Nothing: 2563

Major Trauma Other than Traumatic Paraplegia/Tetraplegia - More money: 4646 Less: 1727 Nothing: 2362

Multiple Sclerosis - More money: 11647 Less: 7970 Nothing: 2277

Unknown/Transfer from AA - More money: 21484 Less: 2813 Nothing: 2099

Asthma - More money: 3693 Less: 2614 Nothing: 1476

Renal Disorders - More money: 1984 Less: 2160 Nothing: 1417

Inflammatory Bowel Disease - More money: 979 Less: 1385 Nothing: 1184

Bowel and Stomach Disease - More money: 1535 Less: 1592 Nothing: 1182

Peripheral vascular Disease - More money: 2783 Less: 1968 Nothing: 1142

Skin Disease - More money: 1388 Less: 1069 Nothing: 1116

AIDS - More money: 552 Less: 1211 Nothing: 977

Multi System Disorders - More money: 2091 Less: 2156 Nothing: 928

Metabolic Disease - More money: 1809 Less: 1928 Nothing: 664

Terminally Ill - More money: 74 Less: 1292 Nothing: 641

Cystic Fibrosis - More money: 723 Less: 358 Nothing: 602

Blood Disorders - More money: 521 Less: 645 Nothing: 490

Dementia - More money: 2722 Less: 204 Nothing: 332

Parkinsons Disease - More money: 2353 Less: 1093 Nothing: 238

Cognitive disorder - other / precise diagnosis not specified - More money: 480 Less: 103 Nothing: 223

Haemophilia - More money: 113 Less: 164 Nothing: 141

Severely Mentally impaired - More money: 91 Less: 260 Nothing: 96

Haemodialysis - More money: 101 Less: 73 Nothing: 78

Traumatic Paraplegia/Tetraplegia - More money: 1104 Less: 687 Nothing: 61

Multiple Allergy Syndrome - More money: 60 Less: 44 Nothing: 45

Motor Neurone Disease - More money: 227 Less: 107 Nothing: 40

Infectious diseases - other / precise diagnosis not specified - More money: 56 Less: 37 Nothing: 39

Infectious diseases: Bacterial disease - Tuberculosis - More money: 37 Less: 37 Nothing: 25

Total Parenteral Nutrition - More money: 17 Less: 11 Nothing: 12

Infectious diseases: Bacterial disease - precise diagnosis not specified - More money: 15 Less: 10 Nothing: 10

Frailty - More money: 52 Less: 42 Nothing: 8

Deaf/Blind - More money: 153 Less: 13 Nothing: 5

Double Amputee - More money: 161 Less: 69 Nothing: ..

Visit link:
DWP: How thousands with arthritis, MS and psychosis have lost benefits under new system - Mirror Online

Read More...

AbbVie Receives European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis…

Monday, December 23rd, 2019

NORTH CHICAGO, Ill., Dec. 18, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Commission (EC) hasapproved RINVOQ (upadacitinib) for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).6 RINVOQ is a once-daily selective and reversible JAK inhibitor and may be used as monotherapy or in combination with methotrexate (MTX).

"We are proud to offer this once-daily tablet as a new treatment option for patients with moderate to severe active rheumatoid arthritis," said Michael Severino, M.D., vice chairman and president, AbbVie. "As a company that has been dedicated to discovering and delivering transformative therapies for people living with rheumatic diseases for nearly two decades, RINVOQ expands our portfolio of treatment options for people living with this disease in Europe."

The EC approval of RINVOQ was supported by data from the global Phase 3 SELECT rheumatoid arthritis program, which evaluated nearly 4,400 patients with moderate to severe active rheumatoid arthritis in five pivotal studies: SELECT-NEXT, SELECT-BEYOND, SELECT-MONOTHERAPY, SELECT-COMPARE and SELECT-EARLY.1-5 The studies include assessments of efficacy, safety and tolerability across a variety of patients, including those who failed or were intolerant to biologic DMARDs and who were nave or inadequate responders (IR) to MTX.1-5

"Nearly 3 million people in Europe are living with rheumatoid arthritis, the majority of whom don't reach remission and may be suffering from pain, fatigue, morning joint stiffness and flares," said Professor Ronald van Vollenhoven, M.D., Ph.D., Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands. "As seen in this large Phase 3 clinical trial program in rheumatoid arthritis, upadacitinib has the potential to significantly improve signs and symptoms of the disease and help more patients achieve remission or low disease activity."

Highlights From the Phase 3 SELECT Rheumatoid Arthritis Program

Across the SELECT Phase 3 studies, RINVOQ met all primary and ranked secondary endpoints.1-6 Overall, both low disease activity (assessed by DAS28-CRP3.2) and clinical remission rates (assessed by DAS28-CRP<2.6) were consistent across patient populations, with or without MTX.1-6

Highlights included:

More information on these trials can be found at http://www.clinicaltrials.gov (NCT02706847, NCT03086343, NCT02629159, NCT02706873, NCT02706951).

Earlier this year, RINVOQ received approval from the U.S. Food and Drug Administration (FDA) for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to MTX.9

About RINVOQ (upadacitinib) in the European Union6

RINVOQ (upadacitinib) is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Important EU Safety Information6

RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.

Use in combination with other potent immunosuppressants is not recommended.

Serious and sometimes fatal infections have been reported in patients receiving upadacitinib. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis have been reported. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/oesophageal candidiasis, and cryptococcosis have been reported with upadacitinib. Prior to initiating upadacitinib, consider the risks and benefits of treatment in patients with chronic or recurrent infection or with a history of a serious or opportunistic infection, in patients who have been exposed to TB or have resided or travelled in areas of endemic TB or endemic mycoses, and in patients with underlying conditions that may predispose them to infection. Upadacitinib therapy should be interrupted if a patient develops a serious or opportunistic infection. As there is a higher incidence of infections in patients 75 years of age, caution should be used when treating this population.

Patients should be screened for TB before starting upadacitinib therapy. Anti-TB therapy should be considered prior to initiation of upadacitinib in patients with previously untreated latent TB or in patients with risk factors for TB infection.

Viral reactivation, including cases of herpes zoster, were reported in clinical studies. Consider interruption of therapy if a patient develops herpes zoster until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should be performed before starting and during therapy with upadacitinib.

The use of live, attenuated vaccines during, or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating upadacitinib, in agreement with current immunization guidelines.

The risk of malignancies, including lymphoma is increased in patients with rheumatoid arthritis (RA). Immunomodulatory medicinal products may increase the risk of malignancies, including lymphoma. The clinical data are currently limited and long-term studies are ongoing. Malignancies, including non-melanoma skin cancer (NMSC), have been reported in patients treated with upadacitinib. Consider the risks and benefits of upadacitinib treatment prior to initiating therapy in patients with a known malignancy other than a successfully treated NMSC or when considering continuing upadacitinib therapy in patients who develop a malignancy.Periodic skin examination is recommended for patients who are at increased risk for skin cancer.

Absolute neutrophil count <1000 cells/mm3, absolute lymphocyte count <500cells/mm3, or haemoglobin levels <8g/dL were reported in <1% of patients in clinical trials. Treatment should not be initiated, or should be temporarily interrupted, in patients with these haematological abnormalities observed during routine patient management.

RA patients have an increased risk for cardiovascular disorders. Patients treated with upadacitinib should have risk factors (e.g., hypertension, hyperlipidaemia) managed as part of usual standard of care.

Upadacitinib treatment was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol. The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined.

Treatment with upadacitinib was associated with an increased incidence of liver enzyme elevation compared to placebo. If increases in ALT or AST are observed during routine patient management and drug-induced liver injury is suspected, upadacitinib therapy should be interrupted until this diagnosis is excluded.

Events of deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients receiving JAK inhibitors, including upadacitinib. Upadacitinib should be used with caution in patients at high risk for DVT/PE. Risk factors that should be considered in determining the patient's risk for DVT/PE include older age, obesity, a medical history of DVT/PE, patients undergoing major surgery, and prolonged immobilisation. If clinical features of DVT/PE occur, upadacitinib treatment should be discontinued and patients should be evaluated promptly, followed by appropriate treatment.

The most commonly reported adverse drug reactions are upper respiratory tract infections (13.5%), nausea (3.5%), increased blood creatine phosphokinase (2.5%), and cough (2.2%). The most common serious adverse reactions were serious infections.

Please see the full SmPC for complete prescribing information at http://www.EMA.europa.eu.Globally, prescribing information varies; refer to the individual country product label for complete information

About HUMIRA in the European Union10

HUMIRA, in combination with methotrexate, is indicated for the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs, including methotrexate, has been inadequate.

Important EU Safety Information10

HUMIRA is contraindicated in patients with active tuberculosis or other severe infections such as sepsis, and opportunistic infections and in patients with moderate to severe heart failure (NYHA class III/IV). It is also contraindicated in patients hypersensitive to the active substance or to any of the excipients; serious allergic reactions including anaphylaxis have been reported. The use of HUMIRA increases the risk of developing serious infections which may, in rare cases, be life-threatening. Rare cases of lymphoma and leukemia have been reported in patients treated with HUMIRA. On rare occasions, a severe type of cancer called hepatosplenic T-cell lymphoma has been observed and often results in death. A risk for the development of malignancies in patients treated with TNF-antagonists cannot be excluded. Rare cases of pancytopenia, aplastic anaemia, demyelinating disease, lupus, lupus-related conditions and Stevens-Johnson syndrome have been reported in patients treated with HUMIRA. The most frequently reported adverse events across all indications included respiratory infections, injection site reactions, headache and musculoskeletal pain.

Please see the full SmPC for complete prescribing information at http://www.ema.europa.eu. Globally, prescribing information varies; refer to the individual country product label for complete information.

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us atwww.abbvie.com. Follow@abbvieon Twitter,Facebook,LinkedInorInstagram.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2018 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References

SOURCE AbbVie

abbvie.com

Link:
AbbVie Receives European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis...

Read More...

How to manage arthritis flare-ups during the holidays – Starts at 60

Monday, December 23rd, 2019

With the help of Howell, weve put together some tips to help you deal with the holiday season.

Theres something about the holidays that makes us want to indulge a little, and rightly so. Its a time for fun, frivolity and enjoying quality time with good friends and good food. But, as tempting as it is, snacking on fruit mince pies or digging into a festive pudding is a big no-no.

Howell says arthritis sufferers should be really careful about what they eat during the festive period, adding that the types of food traditionally eaten at or associated with Christmas aggravate arthritis symptoms.

Every Christmas meal Ive ever had has been packed with ham, sausages, alcohol, chocolate, soft drink and bread, he says. Christmas lunches around Australia are full of sugar, saturated fats, refined carbohydrates, gluten and alcohol all of which are an arthritis sufferers worst nightmare.

Howell adds poor food choices can cause painful arthritis flare-ups, and even more serious health issues in the long-term.

If youre visiting family or friends overseas during the Christmas break and take arthritis medication, make sure you have a doctors certificate with you, Howell advises. You dont want to be caught in a situation where you cant take your meds with you.

A change in weather or humidity can also affect arthritis. Plan ahead and ensure you dress appropriately for the trip.

Howells biggest piece of advice for arthritis sufferers is to stay positive during the Christmas period.

Arthritis may stop you from doing a lot of things at Christmas, he says. You may not be able to eat exactly what you want or be able to participate in the family backyard cricket tournament. But its important to stay positive, especially during Christmas!

Howell recommends talking with your loved ones and suggesting activities that everyone can join in on, such as board games or cards.

Important information: The information provided on this website is of a general nature and information purposes only. It does not take into account your personal health requirements or existing medical conditions. It is not personalised health advice and must not be relied upon as such. Before making any decisions about your health or changes to medication, diet and exercise routines you should determine whether the information is appropriate in terms of your particular circumstances and seek advice from a medical professional.

Link:
How to manage arthritis flare-ups during the holidays - Starts at 60

Read More...

A new look at steroid injections for knee and hip osteoarthritis – Harvard Health Blog – Harvard Health

Monday, December 23rd, 2019

Osteoarthritis is a common and potentially debilitating condition. Its a degenerative joint disease (often called the wear-and-tear type) in which the smooth lining of cartilage becomes thinned and uneven, exposing the bone beneath.

Although osteoarthritis is tightly linked with aging, we now know there is more to it than age alone: genetics, weight, physical activity, and a number of other factors can conspire to make it more likely that someone will develop osteoarthritis while someone else wont. Osteoarthritis is the primary reason that more than a million joints (mostly hips and knees) are replaced each year in the US.

Treatments short of surgery can help but they dont always work well, dont cure the condition, and may be accompanied by side effects. Surgery is usually the last resort, reserved for people who have declining function, unrelenting pain, or both despite trying other treatments such as pain relieving, nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, others) or naproxen (Aleve, others), or injections of steroids or hyaluronic acid (a type of lubricant). Nonmedication approaches can also help, such as loss of excess weight, physical therapy, or use of a cane or brace.

Steroid injections can quickly relieve inflammation in the joints, and the effects may last from several weeks to several months. Ive seen a number of patients who got significant relief from steroid injections every three or four months. But, a new report of one medical centers experience and a review of past research came to some concerning conclusions about joint injections for osteoarthritis of the hip or knee. These included:

Other side effects include a temporary increase in blood sugar, bleeding into the joint, and, quite rarely, infection. And, of course, the injection itself can be painful, although numbing medication is usually provided.

The authors suggest that doctors order x-rays before each injection and not perform injections if there is evidence of any of these complications or unexplained pain. However, its not clear how effective this approach would be.

The findings of this report regarding injections of steroids for knee and hip osteoarthritis are disappointing, especially for those who have not improved with other treatments.

Regarding the benefit of the injections, its important to keep in mind that even if the average benefit of a treatment is small, it does not mean that treatment is useless. Though temporary, some people do report significant improvement with steroid injections.

Its also not entirely clear that the problems described in this study are actually caused by the steroid injections. And, from my own experience, the rates of complications seem high to me. That said, a 2017 study did find that people getting steroid injections had more thinning of joint cartilage than those getting placebo injections.

In my own practice, Ill still offer a steroid injection for osteoarthritis, but only after carefully reviewing the potential risks and benefits. If it is not terribly helpful, I would not encourage repeated injections. On the other hand, if it works well, a limited number of injections (up to three or four per year is a common limit) may reduce pain and improve function and quality of life.

Restricting the injections to those who improve the most and limiting the number of injections each year may be a better strategy than eliminating steroid injections altogether, especially since the most serious side effects are quite rare.

Well need additional studies that examine the type, dosage, and frequency of steroid injections that might provide more benefit than risk. And well need better ways to predict who will improve the most. Until then, I think its important to keep an open mind about just how helpful and how safe steroid injections for osteoarthritis truly are.

Follow me on Twitter @RobShmerling

Read this article:
A new look at steroid injections for knee and hip osteoarthritis - Harvard Health Blog - Harvard Health

Read More...

Page 41«..1020..40414243..5060..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick